2018 ASCO GU Public

John J Coen, MD, presenting Abstract 408, "Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial," during General Session 5

San Francisco, CA - 2018 Genitourinary Cancers Symposium - John J Coen, MD, presenting Abstract 408, "Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial," during General Session 5 at the 2018 Genitourinary Cancers Symposium in San Francisco, CA, here today, Friday February 9, 2018. The conference is the premier meeting on the science and treatment of Genitourinary Cancers from basic research to patient-based studies to larger clinical trials and population analyses in the United States. More than 3,000 experts from around the world are attending the meeting which is sponsored by the American Society of Clinical Oncology, the American Society of Radiation Oncology, and the Society of Urologic Oncology. Photo by © ASCO/Todd Buchanan 2018